0 (0%)
Daily change

Thinking of trading ABBOTT?

    1. The company has seen a growth over the years in its share price. In 2005 it was trading at $17.37, and in 2017 it had increased to $47.50. Its acquisition history has demonstrated that the company has a solid plan to keep this trend going for a long time. 2. The numbers also show a clear bullish trend, Abbott Labs announced 2019 Q1 revenue of $7.5 billion, a 2% increase from the $7.4 billion reported in the same quarter of the previous year. The company reported net earnings of $672 million, or $0.38 per share, on a GAAP basis, compared to $409 million, or $0.23 per share, in the same period in 2018.
Start Trading

Trading CFDs involves significant risk of loss

Get daily trading signals

  • Shares/Indices
  • Forex
  • Gold/Oil

Powered by

Trading CFDs involves significant risk of loss

How would you like to trade ABBOTT?

Fondex cTrader features an impressive array of trading tools that can help you analyse the Forex market with efficiency and precision.
  • Tight spreads & reliable execution
  • 70+ pre-installed indicators
  • Custom indicators
  • 26 time frames
  • Live Sentiment data
  • Chart trading
  • Advanced Take Profit & Stop Loss
  • Depth of Market

Trading CFDs involves significant risk of loss

Fondex cTrader’s Copy functionality enables you to copy strategies from other traders or provide signals and charge a fee.
  • Vast selection of strategies to copy
  • Efficient risk management
  • Can start and stop copying at your will
  • Flexible allocation of funds
  • Detailed performance reports
  • Full transparency & access to historical data

Trading CFDs involves significant risk of loss

Use cBots to monitor and trade multiple Forex pairs at the same time. When you use cBots to trade, an algorithm opens and closes your positions without any decision-making on your part.

For beginners:

  • Great choice of available cBots for various trading strategies and risk tolerance levels
  • Simple Plug and Play functionality

For advanced traders:

  • Ability to create your own cBot or custom indicator

Trading CFDs involves significant risk of loss

Abbott Technologies is an American Health Care Company founded in 1888. The stock, with ticker ABT trades in the NYSE, and it is a component of S&P 100 and S&P 500. It all was started by physician Wallace Calvin Abbot to formulate known drugs but evolved to be much more than that. It split off the research-based pharmaceuticals into AbbVie in 2013. It is worth mentioning that in 1985, the company developed the first HIV blood-screening test. The company started off expanding with its affiliated companies, the first one was in London in 1907, Montreal, Pakistan in 1948, Japan in 1964 with its joint venture with Dainippon Pharmaceutical Co. Abbott entered the European market in France and Italy in 1965 and it is currently the largest healthcare product company in India for the last 100 years. In more recent years, in 2014, the company announced the acquisition of Kalo Pharma International S.L, a holding company. It was bought for $2,9 billion. 2016 the acquisition of Alere took place for $5.8 billion. This made the company the market leader player in the $7 billion point-of-care diagnostic space within the broader $50 billion in-vitro diagnostics market. With the acquisition of Alere, the company also obtain the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier. In January 2019 Abbott exercised its option to purchase Cephea Valve Technologies, Inc. who are developing a less-invasive replacement heart valve for people with mitral valve disease.

1. Some times, direct organic sales increase might not always be equal to a revenue increase. Established pharmaceutical sales for Abbott Labs fell 4.9% year over year. However, this decrease was due to a 10.3% negative impact from currency fluctuations. On an organic basis, established pharmaceutical sales increased by 5.4%. 2. Medical devices undergo clinical trials and are subject to FDA approvals, so there is always the risk of a failed trial or rejection of an application.

Risk Disclaimer Fondex provides this content/feature as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by Fondex, nor any solicitation or incentive provided to subscribe for or sell or purchase any financial instrument or to join and/or terminate any of the trading strategies. The Investor is solely responsible for the choice of the signal provider, choice of trading strategy, the choice whether to sell or purchase any financial instrument on his/her trading account and monitoring of the trading activities. All trading or investments you make must be pursuant to your own unprompted and informed self-directed position. Please keep in mind that past performance is no guarantee of future results.

For more information, please view the 'Risk Disclosure'